^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Glioblastoma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Olutasidenib and Temozolomide in HGG

    Excerpt:
    ...Establish the RP2D of Olutasidenib and Temozolomide (Feasibility cohort)`Assess Progression-Free Survival (PFS) in Grade 3 IDH1-mutant Astrocytoma (Stratum A)`Maximum plasma concentration [Cmax] of Olutasidenib...
    Trial ID:
    NCT06161974
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A study of experimental drug NMS-03305293 in combination with temozolomide in adult patients with a type of brain tumour called glioblastoma

    Excerpt:
    ...Se l'IHC viene eseguito ed è negativo, e il paziente ha < 55 anni, è necessario eseguire il sequenziamento o un test convalidato basato sulla PCR per escludere altre mutazioni IDH1 o IDH2 più frequenti.4. ...
    Trial ID:
    2020-003417-35
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)

    Excerpt:
    ...Documented mutated isocitrate dehydrogenase 1 gene (IDH1) isocitrate dehydrogenase 1 gene (IDH2)status: patients with either wild-type or(IDH) status are eligible....
    Trial ID:
    NCT04926168
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Sci
    Title:

    IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

    Excerpt:
    Progression‐free survival...IDH mutation...MGMT promoter methylation...and 1p19q codeletion were associated with increased PFS...IDH mutation, MGMT promoter methylation, and 1p19q codeletion were strongly correlated with increased OS (P<0.001, P<0.001, P=0.003, respectively)...
    DOI:
    10.1111/j.1349-7006.2011.02134.x
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study

    Excerpt:
    The results of subgroup analysis showed that patients with methylated MGMT in extended group had significantly longer OS and PFS than those in control group; patients with IDH1 mutation benefited more from extended adjuvant TMZ chemotherapy than those with wild-type IDH1....The therapeutic schedule of extended adjuvant TMZ significantly prolonged OS and PFS of patients with newly diagnosed GBM regardless of p53 mutation status, and patients with different MGMT methylation, IDH1 mutation and Ki67 expression level benefited differently from extended adjuvant TMZ chemotherapy.
    DOI:
    10.3389/fonc.2022.1000501
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Pharmaceuticals (Basel)
    Title:

    Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells

    Published date:
    11/24/2020
    Excerpt:
    ...IDH1-mutated GBMSC showed greater sensitivity to the coadministration of temozolomide and meclizine.
    DOI:
    10.3390/ph13120419